7/24/2008

Novartis Vaccines and Diagnostics agreed to supply its trivalent influenza vaccine that will be used in developing Dynavax Technologies' experimental "universal" flu vaccine. In return, Novartis gains the exclusive option to discuss development and marketing deals with Dynavax. Financial terms of the partnership were not disclosed.

Related Summaries